nodes	percent_of_prediction	percent_of_DWPC	metapath
Lansoprazole—ABCG2—Vandetanib—thyroid cancer	0.122	0.204	CbGbCtD
Lansoprazole—CYP1B1—Doxorubicin—thyroid cancer	0.0939	0.157	CbGbCtD
Lansoprazole—ABCG2—Sorafenib—thyroid cancer	0.0736	0.123	CbGbCtD
Lansoprazole—ABCG2—Doxorubicin—thyroid cancer	0.0446	0.0746	CbGbCtD
Lansoprazole—CYP2C8—Sorafenib—thyroid cancer	0.0392	0.0655	CbGbCtD
Lansoprazole—CYP2C19—Sorafenib—thyroid cancer	0.0329	0.0549	CbGbCtD
Lansoprazole—CYP1A2—Sorafenib—thyroid cancer	0.0303	0.0507	CbGbCtD
Lansoprazole—CYP2C9—Sorafenib—thyroid cancer	0.0273	0.0457	CbGbCtD
Lansoprazole—ABCB1—Sorafenib—thyroid cancer	0.0265	0.0443	CbGbCtD
Lansoprazole—CYP3A4—Vandetanib—thyroid cancer	0.0264	0.044	CbGbCtD
Lansoprazole—CYP2D6—Sorafenib—thyroid cancer	0.025	0.0418	CbGbCtD
Lansoprazole—ATP4A—larynx—thyroid cancer	0.0168	0.462	CbGeAlD
Lansoprazole—ABCB1—Doxorubicin—thyroid cancer	0.0161	0.0269	CbGbCtD
Lansoprazole—CYP3A4—Sorafenib—thyroid cancer	0.0159	0.0266	CbGbCtD
Lansoprazole—CYP2D6—Doxorubicin—thyroid cancer	0.0152	0.0253	CbGbCtD
Lansoprazole—CYP3A4—Doxorubicin—thyroid cancer	0.00964	0.0161	CbGbCtD
Lansoprazole—ATP4A—neck—thyroid cancer	0.00446	0.123	CbGeAlD
Lansoprazole—MAPT—thyroid gland—thyroid cancer	0.00286	0.0786	CbGeAlD
Lansoprazole—ATP4A—head—thyroid cancer	0.00188	0.0518	CbGeAlD
Lansoprazole—MAPT—lymph node—thyroid cancer	0.00178	0.0488	CbGeAlD
Lansoprazole—ABCG2—saliva-secreting gland—thyroid cancer	0.00103	0.0283	CbGeAlD
Lansoprazole—CYP1B1—thyroid gland—thyroid cancer	0.000846	0.0232	CbGeAlD
Lansoprazole—CYP1A1—trachea—thyroid cancer	0.000756	0.0208	CbGeAlD
Lansoprazole—CYP1B1—head—thyroid cancer	0.00075	0.0206	CbGeAlD
Lansoprazole—ABCG2—thyroid gland—thyroid cancer	0.00063	0.0173	CbGeAlD
Lansoprazole—CYP1A2—thyroid gland—thyroid cancer	0.000606	0.0166	CbGeAlD
Lansoprazole—CYP1A1—thyroid gland—thyroid cancer	0.000598	0.0164	CbGeAlD
Lansoprazole—CYP1A1—head—thyroid cancer	0.00053	0.0146	CbGeAlD
Lansoprazole—CYP1B1—lymph node—thyroid cancer	0.000525	0.0144	CbGeAlD
Lansoprazole—ABCB1—trachea—thyroid cancer	0.000393	0.0108	CbGeAlD
Lansoprazole—ABCG2—lymph node—thyroid cancer	0.000391	0.0107	CbGeAlD
Lansoprazole—CYP2D6—head—thyroid cancer	0.000383	0.0105	CbGeAlD
Lansoprazole—CYP1A1—lymph node—thyroid cancer	0.000371	0.0102	CbGeAlD
Lansoprazole—ABCB1—thyroid gland—thyroid cancer	0.000311	0.00853	CbGeAlD
Lansoprazole—ABCB1—head—thyroid cancer	0.000276	0.00757	CbGeAlD
Lansoprazole—ABCB1—lymph node—thyroid cancer	0.000193	0.0053	CbGeAlD
Lansoprazole—Dehydration—Doxorubicin—thyroid cancer	0.000189	0.000602	CcSEcCtD
Lansoprazole—Eosinophilia—Epirubicin—thyroid cancer	0.000188	0.000598	CcSEcCtD
Lansoprazole—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000188	0.000597	CcSEcCtD
Lansoprazole—Dry skin—Doxorubicin—thyroid cancer	0.000186	0.000593	CcSEcCtD
Lansoprazole—Pancreatitis—Epirubicin—thyroid cancer	0.000186	0.000593	CcSEcCtD
Lansoprazole—Vomiting—Sorafenib—thyroid cancer	0.000186	0.000591	CcSEcCtD
Lansoprazole—Hypokalaemia—Doxorubicin—thyroid cancer	0.000185	0.000589	CcSEcCtD
Lansoprazole—Angina pectoris—Epirubicin—thyroid cancer	0.000185	0.000589	CcSEcCtD
Lansoprazole—Rash—Sorafenib—thyroid cancer	0.000184	0.000586	CcSEcCtD
Lansoprazole—Dermatitis—Sorafenib—thyroid cancer	0.000184	0.000586	CcSEcCtD
Lansoprazole—Breast disorder—Doxorubicin—thyroid cancer	0.000184	0.000585	CcSEcCtD
Lansoprazole—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000183	0.000583	CcSEcCtD
Lansoprazole—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000183	0.000583	CcSEcCtD
Lansoprazole—Headache—Sorafenib—thyroid cancer	0.000183	0.000583	CcSEcCtD
Lansoprazole—Bronchitis—Epirubicin—thyroid cancer	0.000183	0.000581	CcSEcCtD
Lansoprazole—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000182	0.000579	CcSEcCtD
Lansoprazole—Pancytopenia—Epirubicin—thyroid cancer	0.00018	0.000574	CcSEcCtD
Lansoprazole—Gastritis—Doxorubicin—thyroid cancer	0.00018	0.000573	CcSEcCtD
Lansoprazole—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000179	0.000571	CcSEcCtD
Lansoprazole—Muscular weakness—Doxorubicin—thyroid cancer	0.000179	0.000571	CcSEcCtD
Lansoprazole—Dysuria—Epirubicin—thyroid cancer	0.000178	0.000565	CcSEcCtD
Lansoprazole—Neutropenia—Epirubicin—thyroid cancer	0.000178	0.000565	CcSEcCtD
Lansoprazole—Abdominal distension—Doxorubicin—thyroid cancer	0.000177	0.000563	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000176	0.000562	CcSEcCtD
Lansoprazole—Asthma—Doxorubicin—thyroid cancer	0.000176	0.000559	CcSEcCtD
Lansoprazole—Dysphagia—Doxorubicin—thyroid cancer	0.000176	0.000559	CcSEcCtD
Lansoprazole—Influenza—Doxorubicin—thyroid cancer	0.000176	0.000559	CcSEcCtD
Lansoprazole—Pollakiuria—Epirubicin—thyroid cancer	0.000175	0.000558	CcSEcCtD
Lansoprazole—Eosinophilia—Doxorubicin—thyroid cancer	0.000174	0.000554	CcSEcCtD
Lansoprazole—Nausea—Sorafenib—thyroid cancer	0.000174	0.000552	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000173	0.000552	CcSEcCtD
Lansoprazole—Weight increased—Epirubicin—thyroid cancer	0.000173	0.00055	CcSEcCtD
Lansoprazole—Pancreatitis—Doxorubicin—thyroid cancer	0.000172	0.000548	CcSEcCtD
Lansoprazole—Hyperglycaemia—Epirubicin—thyroid cancer	0.000171	0.000545	CcSEcCtD
Lansoprazole—Angina pectoris—Doxorubicin—thyroid cancer	0.000171	0.000545	CcSEcCtD
Lansoprazole—Pneumonia—Epirubicin—thyroid cancer	0.00017	0.000542	CcSEcCtD
Lansoprazole—Infestation—Epirubicin—thyroid cancer	0.000169	0.000539	CcSEcCtD
Lansoprazole—Infestation NOS—Epirubicin—thyroid cancer	0.000169	0.000539	CcSEcCtD
Lansoprazole—Bronchitis—Doxorubicin—thyroid cancer	0.000169	0.000538	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000168	0.000534	CcSEcCtD
Lansoprazole—Pancytopenia—Doxorubicin—thyroid cancer	0.000167	0.000531	CcSEcCtD
Lansoprazole—Renal failure—Epirubicin—thyroid cancer	0.000166	0.00053	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000166	0.000528	CcSEcCtD
Lansoprazole—Stomatitis—Epirubicin—thyroid cancer	0.000165	0.000525	CcSEcCtD
Lansoprazole—Jaundice—Epirubicin—thyroid cancer	0.000165	0.000525	CcSEcCtD
Lansoprazole—Conjunctivitis—Epirubicin—thyroid cancer	0.000165	0.000524	CcSEcCtD
Lansoprazole—Urinary tract infection—Epirubicin—thyroid cancer	0.000165	0.000524	CcSEcCtD
Lansoprazole—Dysuria—Doxorubicin—thyroid cancer	0.000164	0.000523	CcSEcCtD
Lansoprazole—Neutropenia—Doxorubicin—thyroid cancer	0.000164	0.000523	CcSEcCtD
Lansoprazole—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000163	0.00052	CcSEcCtD
Lansoprazole—Sweating—Epirubicin—thyroid cancer	0.000162	0.000517	CcSEcCtD
Lansoprazole—Pollakiuria—Doxorubicin—thyroid cancer	0.000162	0.000517	CcSEcCtD
Lansoprazole—Haematuria—Epirubicin—thyroid cancer	0.000161	0.000514	CcSEcCtD
Lansoprazole—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00016	0.00051	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00016	0.00051	CcSEcCtD
Lansoprazole—Weight increased—Doxorubicin—thyroid cancer	0.00016	0.000509	CcSEcCtD
Lansoprazole—Epistaxis—Epirubicin—thyroid cancer	0.00016	0.000508	CcSEcCtD
Lansoprazole—Sinusitis—Epirubicin—thyroid cancer	0.000159	0.000506	CcSEcCtD
Lansoprazole—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000159	0.000504	CcSEcCtD
Lansoprazole—Agranulocytosis—Epirubicin—thyroid cancer	0.000158	0.000503	CcSEcCtD
Lansoprazole—Pneumonia—Doxorubicin—thyroid cancer	0.000158	0.000501	CcSEcCtD
Lansoprazole—Infestation NOS—Doxorubicin—thyroid cancer	0.000157	0.000499	CcSEcCtD
Lansoprazole—Infestation—Doxorubicin—thyroid cancer	0.000157	0.000499	CcSEcCtD
Lansoprazole—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000155	0.000494	CcSEcCtD
Lansoprazole—Bradycardia—Epirubicin—thyroid cancer	0.000155	0.000492	CcSEcCtD
Lansoprazole—Renal failure—Doxorubicin—thyroid cancer	0.000154	0.00049	CcSEcCtD
Lansoprazole—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000154	0.000489	CcSEcCtD
Lansoprazole—Stomatitis—Doxorubicin—thyroid cancer	0.000153	0.000486	CcSEcCtD
Lansoprazole—Jaundice—Doxorubicin—thyroid cancer	0.000153	0.000486	CcSEcCtD
Lansoprazole—Rhinitis—Epirubicin—thyroid cancer	0.000152	0.000485	CcSEcCtD
Lansoprazole—Conjunctivitis—Doxorubicin—thyroid cancer	0.000152	0.000485	CcSEcCtD
Lansoprazole—Urinary tract infection—Doxorubicin—thyroid cancer	0.000152	0.000485	CcSEcCtD
Lansoprazole—Hepatitis—Epirubicin—thyroid cancer	0.000152	0.000484	CcSEcCtD
Lansoprazole—Hypoaesthesia—Epirubicin—thyroid cancer	0.000151	0.000481	CcSEcCtD
Lansoprazole—Pharyngitis—Epirubicin—thyroid cancer	0.000151	0.00048	CcSEcCtD
Lansoprazole—Sweating—Doxorubicin—thyroid cancer	0.00015	0.000478	CcSEcCtD
Lansoprazole—Urinary tract disorder—Epirubicin—thyroid cancer	0.00015	0.000478	CcSEcCtD
Lansoprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00015	0.00295	CbGpPWpGaD
Lansoprazole—Oedema peripheral—Epirubicin—thyroid cancer	0.00015	0.000477	CcSEcCtD
Lansoprazole—Haematuria—Doxorubicin—thyroid cancer	0.000149	0.000475	CcSEcCtD
Lansoprazole—Connective tissue disorder—Epirubicin—thyroid cancer	0.000149	0.000475	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—NRAS—thyroid cancer	0.000149	0.00294	CbGpPWpGaD
Lansoprazole—Urethral disorder—Epirubicin—thyroid cancer	0.000149	0.000474	CcSEcCtD
Lansoprazole—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000148	0.000472	CcSEcCtD
Lansoprazole—Epistaxis—Doxorubicin—thyroid cancer	0.000148	0.00047	CcSEcCtD
Lansoprazole—Sinusitis—Doxorubicin—thyroid cancer	0.000147	0.000468	CcSEcCtD
Lansoprazole—Visual impairment—Epirubicin—thyroid cancer	0.000146	0.000466	CcSEcCtD
Lansoprazole—Agranulocytosis—Doxorubicin—thyroid cancer	0.000146	0.000465	CcSEcCtD
Lansoprazole—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000145	0.00286	CbGpPWpGaD
Lansoprazole—Erythema multiforme—Epirubicin—thyroid cancer	0.000144	0.000457	CcSEcCtD
Lansoprazole—Bradycardia—Doxorubicin—thyroid cancer	0.000143	0.000456	CcSEcCtD
Lansoprazole—ABCG2—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000142	0.0028	CbGpPWpGaD
Lansoprazole—Eye disorder—Epirubicin—thyroid cancer	0.000142	0.000452	CcSEcCtD
Lansoprazole—Tinnitus—Epirubicin—thyroid cancer	0.000142	0.000451	CcSEcCtD
Lansoprazole—CYP1B1—Biological oxidations—RXRA—thyroid cancer	0.000141	0.00278	CbGpPWpGaD
Lansoprazole—Cardiac disorder—Epirubicin—thyroid cancer	0.000141	0.000449	CcSEcCtD
Lansoprazole—Rhinitis—Doxorubicin—thyroid cancer	0.000141	0.000449	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—MINPP1—thyroid cancer	0.000141	0.00277	CbGpPWpGaD
Lansoprazole—Hepatitis—Doxorubicin—thyroid cancer	0.000141	0.000448	CcSEcCtD
Lansoprazole—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00014	0.000445	CcSEcCtD
Lansoprazole—Pharyngitis—Doxorubicin—thyroid cancer	0.00014	0.000444	CcSEcCtD
Lansoprazole—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000139	0.000442	CcSEcCtD
Lansoprazole—Oedema peripheral—Doxorubicin—thyroid cancer	0.000139	0.000441	CcSEcCtD
Lansoprazole—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000138	0.00044	CcSEcCtD
Lansoprazole—Angiopathy—Epirubicin—thyroid cancer	0.000138	0.000439	CcSEcCtD
Lansoprazole—Urethral disorder—Doxorubicin—thyroid cancer	0.000138	0.000439	CcSEcCtD
Lansoprazole—Immune system disorder—Epirubicin—thyroid cancer	0.000137	0.000437	CcSEcCtD
Lansoprazole—CYP4A11—Metabolism—NDUFA13—thyroid cancer	0.000137	0.0027	CbGpPWpGaD
Lansoprazole—Mediastinal disorder—Epirubicin—thyroid cancer	0.000137	0.000436	CcSEcCtD
Lansoprazole—Chills—Epirubicin—thyroid cancer	0.000136	0.000434	CcSEcCtD
Lansoprazole—Arrhythmia—Epirubicin—thyroid cancer	0.000136	0.000432	CcSEcCtD
Lansoprazole—Visual impairment—Doxorubicin—thyroid cancer	0.000136	0.000431	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000135	0.00266	CbGpPWpGaD
Lansoprazole—Alopecia—Epirubicin—thyroid cancer	0.000134	0.000427	CcSEcCtD
Lansoprazole—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000134	0.00264	CbGpPWpGaD
Lansoprazole—CYP4A11—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000134	0.00263	CbGpPWpGaD
Lansoprazole—Mental disorder—Epirubicin—thyroid cancer	0.000133	0.000424	CcSEcCtD
Lansoprazole—Erythema multiforme—Doxorubicin—thyroid cancer	0.000133	0.000423	CcSEcCtD
Lansoprazole—Malnutrition—Epirubicin—thyroid cancer	0.000132	0.000421	CcSEcCtD
Lansoprazole—Erythema—Epirubicin—thyroid cancer	0.000132	0.000421	CcSEcCtD
Lansoprazole—Eye disorder—Doxorubicin—thyroid cancer	0.000131	0.000418	CcSEcCtD
Lansoprazole—Tinnitus—Doxorubicin—thyroid cancer	0.000131	0.000417	CcSEcCtD
Lansoprazole—Cardiac disorder—Doxorubicin—thyroid cancer	0.000131	0.000415	CcSEcCtD
Lansoprazole—Flatulence—Epirubicin—thyroid cancer	0.00013	0.000415	CcSEcCtD
Lansoprazole—Tension—Epirubicin—thyroid cancer	0.00013	0.000413	CcSEcCtD
Lansoprazole—Dysgeusia—Epirubicin—thyroid cancer	0.00013	0.000412	CcSEcCtD
Lansoprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000129	0.00254	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—CHST14—thyroid cancer	0.000129	0.00254	CbGpPWpGaD
Lansoprazole—Nervousness—Epirubicin—thyroid cancer	0.000129	0.000409	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—KRAS—thyroid cancer	0.000128	0.00253	CbGpPWpGaD
Lansoprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000128	0.00252	CbGpPWpGaD
Lansoprazole—Back pain—Epirubicin—thyroid cancer	0.000128	0.000407	CcSEcCtD
Lansoprazole—Angiopathy—Doxorubicin—thyroid cancer	0.000128	0.000406	CcSEcCtD
Lansoprazole—Muscle spasms—Epirubicin—thyroid cancer	0.000127	0.000405	CcSEcCtD
Lansoprazole—Immune system disorder—Doxorubicin—thyroid cancer	0.000127	0.000404	CcSEcCtD
Lansoprazole—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000127	0.000403	CcSEcCtD
Lansoprazole—Chills—Doxorubicin—thyroid cancer	0.000126	0.000402	CcSEcCtD
Lansoprazole—Arrhythmia—Doxorubicin—thyroid cancer	0.000126	0.0004	CcSEcCtD
Lansoprazole—Vision blurred—Epirubicin—thyroid cancer	0.000125	0.000397	CcSEcCtD
Lansoprazole—CYP1A1—PPARA activates gene expression—RXRA—thyroid cancer	0.000125	0.00245	CbGpPWpGaD
Lansoprazole—Alopecia—Doxorubicin—thyroid cancer	0.000124	0.000396	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000124	0.00244	CbGpPWpGaD
Lansoprazole—MAPT—BDNF signaling pathway—HRAS—thyroid cancer	0.000124	0.00243	CbGpPWpGaD
Lansoprazole—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000123	0.00243	CbGpPWpGaD
Lansoprazole—Mental disorder—Doxorubicin—thyroid cancer	0.000123	0.000392	CcSEcCtD
Lansoprazole—Ill-defined disorder—Epirubicin—thyroid cancer	0.000123	0.000391	CcSEcCtD
Lansoprazole—Malnutrition—Doxorubicin—thyroid cancer	0.000122	0.00039	CcSEcCtD
Lansoprazole—Erythema—Doxorubicin—thyroid cancer	0.000122	0.00039	CcSEcCtD
Lansoprazole—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000122	0.00241	CbGpPWpGaD
Lansoprazole—Anaemia—Epirubicin—thyroid cancer	0.000122	0.000389	CcSEcCtD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000122	0.0024	CbGpPWpGaD
Lansoprazole—MAPT—Apoptosis—TP53—thyroid cancer	0.000122	0.0024	CbGpPWpGaD
Lansoprazole—Agitation—Epirubicin—thyroid cancer	0.000122	0.000387	CcSEcCtD
Lansoprazole—Flatulence—Doxorubicin—thyroid cancer	0.000121	0.000384	CcSEcCtD
Lansoprazole—Tension—Doxorubicin—thyroid cancer	0.00012	0.000382	CcSEcCtD
Lansoprazole—Dysgeusia—Doxorubicin—thyroid cancer	0.00012	0.000382	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—NDUFA13—thyroid cancer	0.00012	0.00236	CbGpPWpGaD
Lansoprazole—Malaise—Epirubicin—thyroid cancer	0.000119	0.00038	CcSEcCtD
Lansoprazole—Nervousness—Doxorubicin—thyroid cancer	0.000119	0.000378	CcSEcCtD
Lansoprazole—Vertigo—Epirubicin—thyroid cancer	0.000119	0.000378	CcSEcCtD
Lansoprazole—Syncope—Epirubicin—thyroid cancer	0.000119	0.000378	CcSEcCtD
Lansoprazole—Leukopenia—Epirubicin—thyroid cancer	0.000118	0.000377	CcSEcCtD
Lansoprazole—Back pain—Doxorubicin—thyroid cancer	0.000118	0.000377	CcSEcCtD
Lansoprazole—Muscle spasms—Doxorubicin—thyroid cancer	0.000118	0.000375	CcSEcCtD
Lansoprazole—Palpitations—Epirubicin—thyroid cancer	0.000117	0.000372	CcSEcCtD
Lansoprazole—Loss of consciousness—Epirubicin—thyroid cancer	0.000116	0.00037	CcSEcCtD
Lansoprazole—CYP1A1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000116	0.00229	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000116	0.00229	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000116	0.00228	CbGpPWpGaD
Lansoprazole—Cough—Epirubicin—thyroid cancer	0.000115	0.000367	CcSEcCtD
Lansoprazole—Vision blurred—Doxorubicin—thyroid cancer	0.000115	0.000367	CcSEcCtD
Lansoprazole—CYP1B1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000115	0.00226	CbGpPWpGaD
Lansoprazole—Convulsion—Epirubicin—thyroid cancer	0.000115	0.000365	CcSEcCtD
Lansoprazole—Hypertension—Epirubicin—thyroid cancer	0.000114	0.000364	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—TP53—thyroid cancer	0.000114	0.00225	CbGpPWpGaD
Lansoprazole—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000114	0.000362	CcSEcCtD
Lansoprazole—Anaemia—Doxorubicin—thyroid cancer	0.000113	0.00036	CcSEcCtD
Lansoprazole—Arthralgia—Epirubicin—thyroid cancer	0.000113	0.000358	CcSEcCtD
Lansoprazole—Myalgia—Epirubicin—thyroid cancer	0.000113	0.000358	CcSEcCtD
Lansoprazole—Chest pain—Epirubicin—thyroid cancer	0.000113	0.000358	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—CHST14—thyroid cancer	0.000113	0.00222	CbGpPWpGaD
Lansoprazole—Agitation—Doxorubicin—thyroid cancer	0.000113	0.000358	CcSEcCtD
Lansoprazole—Anxiety—Epirubicin—thyroid cancer	0.000112	0.000357	CcSEcCtD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000112	0.000356	CcSEcCtD
Lansoprazole—Discomfort—Epirubicin—thyroid cancer	0.000111	0.000354	CcSEcCtD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000111	0.00219	CbGpPWpGaD
Lansoprazole—Malaise—Doxorubicin—thyroid cancer	0.00011	0.000351	CcSEcCtD
Lansoprazole—Dry mouth—Epirubicin—thyroid cancer	0.00011	0.000351	CcSEcCtD
Lansoprazole—Vertigo—Doxorubicin—thyroid cancer	0.00011	0.00035	CcSEcCtD
Lansoprazole—Syncope—Doxorubicin—thyroid cancer	0.00011	0.000349	CcSEcCtD
Lansoprazole—Leukopenia—Doxorubicin—thyroid cancer	0.00011	0.000349	CcSEcCtD
Lansoprazole—MAPT—BDNF signaling pathway—AKT1—thyroid cancer	0.000109	0.00215	CbGpPWpGaD
Lansoprazole—Confusional state—Epirubicin—thyroid cancer	0.000109	0.000347	CcSEcCtD
Lansoprazole—Palpitations—Doxorubicin—thyroid cancer	0.000108	0.000344	CcSEcCtD
Lansoprazole—Oedema—Epirubicin—thyroid cancer	0.000108	0.000344	CcSEcCtD
Lansoprazole—Anaphylactic shock—Epirubicin—thyroid cancer	0.000108	0.000344	CcSEcCtD
Lansoprazole—Loss of consciousness—Doxorubicin—thyroid cancer	0.000108	0.000342	CcSEcCtD
Lansoprazole—Infection—Epirubicin—thyroid cancer	0.000107	0.000341	CcSEcCtD
Lansoprazole—Cough—Doxorubicin—thyroid cancer	0.000107	0.00034	CcSEcCtD
Lansoprazole—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000107	0.0021	CbGpPWpGaD
Lansoprazole—Shock—Epirubicin—thyroid cancer	0.000106	0.000338	CcSEcCtD
Lansoprazole—Convulsion—Doxorubicin—thyroid cancer	0.000106	0.000338	CcSEcCtD
Lansoprazole—Nervous system disorder—Epirubicin—thyroid cancer	0.000106	0.000337	CcSEcCtD
Lansoprazole—Thrombocytopenia—Epirubicin—thyroid cancer	0.000106	0.000336	CcSEcCtD
Lansoprazole—Hypertension—Doxorubicin—thyroid cancer	0.000106	0.000336	CcSEcCtD
Lansoprazole—Tachycardia—Epirubicin—thyroid cancer	0.000105	0.000335	CcSEcCtD
Lansoprazole—Skin disorder—Epirubicin—thyroid cancer	0.000105	0.000334	CcSEcCtD
Lansoprazole—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000105	0.00206	CbGpPWpGaD
Lansoprazole—Hyperhidrosis—Epirubicin—thyroid cancer	0.000104	0.000332	CcSEcCtD
Lansoprazole—Arthralgia—Doxorubicin—thyroid cancer	0.000104	0.000332	CcSEcCtD
Lansoprazole—Chest pain—Doxorubicin—thyroid cancer	0.000104	0.000332	CcSEcCtD
Lansoprazole—Myalgia—Doxorubicin—thyroid cancer	0.000104	0.000332	CcSEcCtD
Lansoprazole—Anxiety—Doxorubicin—thyroid cancer	0.000104	0.000331	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—MINPP1—thyroid cancer	0.000104	0.00204	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—HPGD—thyroid cancer	0.000104	0.00204	CbGpPWpGaD
Lansoprazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000104	0.000329	CcSEcCtD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	0.000103	0.00203	CbGpPWpGaD
Lansoprazole—Discomfort—Doxorubicin—thyroid cancer	0.000103	0.000328	CcSEcCtD
Lansoprazole—Anorexia—Epirubicin—thyroid cancer	0.000103	0.000328	CcSEcCtD
Lansoprazole—MAPT—Apoptosis—AKT1—thyroid cancer	0.000103	0.00202	CbGpPWpGaD
Lansoprazole—Dry mouth—Doxorubicin—thyroid cancer	0.000102	0.000324	CcSEcCtD
Lansoprazole—Hypotension—Epirubicin—thyroid cancer	0.000101	0.000321	CcSEcCtD
Lansoprazole—Confusional state—Doxorubicin—thyroid cancer	0.000101	0.000321	CcSEcCtD
Lansoprazole—Anaphylactic shock—Doxorubicin—thyroid cancer	9.99e-05	0.000318	CcSEcCtD
Lansoprazole—Oedema—Doxorubicin—thyroid cancer	9.99e-05	0.000318	CcSEcCtD
Lansoprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	9.95e-05	0.00196	CbGpPWpGaD
Lansoprazole—Infection—Doxorubicin—thyroid cancer	9.93e-05	0.000316	CcSEcCtD
Lansoprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	9.9e-05	0.00195	CbGpPWpGaD
Lansoprazole—Musculoskeletal discomfort—Epirubicin—thyroid cancer	9.84e-05	0.000313	CcSEcCtD
Lansoprazole—Shock—Doxorubicin—thyroid cancer	9.83e-05	0.000313	CcSEcCtD
Lansoprazole—Nervous system disorder—Doxorubicin—thyroid cancer	9.8e-05	0.000312	CcSEcCtD
Lansoprazole—Thrombocytopenia—Doxorubicin—thyroid cancer	9.78e-05	0.000311	CcSEcCtD
Lansoprazole—Insomnia—Epirubicin—thyroid cancer	9.77e-05	0.000311	CcSEcCtD
Lansoprazole—Tachycardia—Doxorubicin—thyroid cancer	9.75e-05	0.00031	CcSEcCtD
Lansoprazole—Skin disorder—Doxorubicin—thyroid cancer	9.71e-05	0.000309	CcSEcCtD
Lansoprazole—Paraesthesia—Epirubicin—thyroid cancer	9.7e-05	0.000309	CcSEcCtD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	9.66e-05	0.0019	CbGpPWpGaD
Lansoprazole—Hyperhidrosis—Doxorubicin—thyroid cancer	9.66e-05	0.000307	CcSEcCtD
Lansoprazole—MAPT—MAPK Signaling Pathway—AKT1—thyroid cancer	9.64e-05	0.0019	CbGpPWpGaD
Lansoprazole—Dyspnoea—Epirubicin—thyroid cancer	9.63e-05	0.000306	CcSEcCtD
Lansoprazole—Somnolence—Epirubicin—thyroid cancer	9.6e-05	0.000306	CcSEcCtD
Lansoprazole—Anorexia—Doxorubicin—thyroid cancer	9.52e-05	0.000303	CcSEcCtD
Lansoprazole—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	9.51e-05	0.00187	CbGpPWpGaD
Lansoprazole—Dyspepsia—Epirubicin—thyroid cancer	9.51e-05	0.000303	CcSEcCtD
Lansoprazole—ABCG2—Metabolism—MINPP1—thyroid cancer	9.45e-05	0.00186	CbGpPWpGaD
Lansoprazole—Decreased appetite—Epirubicin—thyroid cancer	9.39e-05	0.000299	CcSEcCtD
Lansoprazole—Hypotension—Doxorubicin—thyroid cancer	9.34e-05	0.000297	CcSEcCtD
Lansoprazole—Gastrointestinal disorder—Epirubicin—thyroid cancer	9.32e-05	0.000297	CcSEcCtD
Lansoprazole—Fatigue—Epirubicin—thyroid cancer	9.31e-05	0.000296	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.26e-05	0.00182	CbGpPWpGaD
Lansoprazole—Pain—Epirubicin—thyroid cancer	9.23e-05	0.000294	CcSEcCtD
Lansoprazole—Constipation—Epirubicin—thyroid cancer	9.23e-05	0.000294	CcSEcCtD
Lansoprazole—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	9.1e-05	0.00029	CcSEcCtD
Lansoprazole—CYP2C18—Metabolism—HPGD—thyroid cancer	9.08e-05	0.00179	CbGpPWpGaD
Lansoprazole—Insomnia—Doxorubicin—thyroid cancer	9.04e-05	0.000288	CcSEcCtD
Lansoprazole—Paraesthesia—Doxorubicin—thyroid cancer	8.97e-05	0.000286	CcSEcCtD
Lansoprazole—Dyspnoea—Doxorubicin—thyroid cancer	8.91e-05	0.000283	CcSEcCtD
Lansoprazole—Feeling abnormal—Epirubicin—thyroid cancer	8.9e-05	0.000283	CcSEcCtD
Lansoprazole—Somnolence—Doxorubicin—thyroid cancer	8.88e-05	0.000283	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—NDUFA13—thyroid cancer	8.83e-05	0.00174	CbGpPWpGaD
Lansoprazole—Gastrointestinal pain—Epirubicin—thyroid cancer	8.83e-05	0.000281	CcSEcCtD
Lansoprazole—Dyspepsia—Doxorubicin—thyroid cancer	8.8e-05	0.00028	CcSEcCtD
Lansoprazole—CYP1A1—Biological oxidations—RXRA—thyroid cancer	8.71e-05	0.00171	CbGpPWpGaD
Lansoprazole—MAPT—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	8.7e-05	0.00171	CbGpPWpGaD
Lansoprazole—Decreased appetite—Doxorubicin—thyroid cancer	8.69e-05	0.000276	CcSEcCtD
Lansoprazole—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	8.67e-05	0.00171	CbGpPWpGaD
Lansoprazole—Gastrointestinal disorder—Doxorubicin—thyroid cancer	8.63e-05	0.000275	CcSEcCtD
Lansoprazole—Fatigue—Doxorubicin—thyroid cancer	8.61e-05	0.000274	CcSEcCtD
Lansoprazole—Urticaria—Epirubicin—thyroid cancer	8.58e-05	0.000273	CcSEcCtD
Lansoprazole—Pain—Doxorubicin—thyroid cancer	8.54e-05	0.000272	CcSEcCtD
Lansoprazole—Constipation—Doxorubicin—thyroid cancer	8.54e-05	0.000272	CcSEcCtD
Lansoprazole—Abdominal pain—Epirubicin—thyroid cancer	8.54e-05	0.000272	CcSEcCtD
Lansoprazole—Body temperature increased—Epirubicin—thyroid cancer	8.54e-05	0.000272	CcSEcCtD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	8.49e-05	0.00167	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.43e-05	0.00166	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	8.4e-05	0.00165	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	8.32e-05	0.00164	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—CHST14—thyroid cancer	8.3e-05	0.00163	CbGpPWpGaD
Lansoprazole—Feeling abnormal—Doxorubicin—thyroid cancer	8.23e-05	0.000262	CcSEcCtD
Lansoprazole—Gastrointestinal pain—Doxorubicin—thyroid cancer	8.17e-05	0.00026	CcSEcCtD
Lansoprazole—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	8.07e-05	0.00159	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—NDUFA13—thyroid cancer	8.04e-05	0.00158	CbGpPWpGaD
Lansoprazole—CYP2C8—Biological oxidations—RXRA—thyroid cancer	7.98e-05	0.00157	CbGpPWpGaD
Lansoprazole—Hypersensitivity—Epirubicin—thyroid cancer	7.96e-05	0.000253	CcSEcCtD
Lansoprazole—Urticaria—Doxorubicin—thyroid cancer	7.94e-05	0.000253	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	7.92e-05	0.00156	CbGpPWpGaD
Lansoprazole—Body temperature increased—Doxorubicin—thyroid cancer	7.9e-05	0.000251	CcSEcCtD
Lansoprazole—Abdominal pain—Doxorubicin—thyroid cancer	7.9e-05	0.000251	CcSEcCtD
Lansoprazole—CYP1A1—PPARA activates gene expression—PPARG—thyroid cancer	7.86e-05	0.00155	CbGpPWpGaD
Lansoprazole—Asthenia—Epirubicin—thyroid cancer	7.75e-05	0.000247	CcSEcCtD
Lansoprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	7.69e-05	0.00151	CbGpPWpGaD
Lansoprazole—Pruritus—Epirubicin—thyroid cancer	7.64e-05	0.000243	CcSEcCtD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	7.57e-05	0.00149	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—CHST14—thyroid cancer	7.55e-05	0.00149	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—CP—thyroid cancer	7.47e-05	0.00147	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—TPR—thyroid cancer	7.47e-05	0.00147	CbGpPWpGaD
Lansoprazole—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	7.41e-05	0.00146	CbGpPWpGaD
Lansoprazole—Diarrhoea—Epirubicin—thyroid cancer	7.39e-05	0.000235	CcSEcCtD
Lansoprazole—Hypersensitivity—Doxorubicin—thyroid cancer	7.36e-05	0.000234	CcSEcCtD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.35e-05	0.00145	CbGpPWpGaD
Lansoprazole—Asthenia—Doxorubicin—thyroid cancer	7.17e-05	0.000228	CcSEcCtD
Lansoprazole—Dizziness—Epirubicin—thyroid cancer	7.14e-05	0.000227	CcSEcCtD
Lansoprazole—CYP2C19—Biological oxidations—RXRA—thyroid cancer	7.13e-05	0.0014	CbGpPWpGaD
Lansoprazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	7.07e-05	0.00139	CbGpPWpGaD
Lansoprazole—Pruritus—Doxorubicin—thyroid cancer	7.07e-05	0.000225	CcSEcCtD
Lansoprazole—ABCG2—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	6.91e-05	0.00136	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	6.91e-05	0.00136	CbGpPWpGaD
Lansoprazole—Vomiting—Epirubicin—thyroid cancer	6.87e-05	0.000219	CcSEcCtD
Lansoprazole—Diarrhoea—Doxorubicin—thyroid cancer	6.84e-05	0.000218	CcSEcCtD
Lansoprazole—Rash—Epirubicin—thyroid cancer	6.81e-05	0.000217	CcSEcCtD
Lansoprazole—Dermatitis—Epirubicin—thyroid cancer	6.8e-05	0.000216	CcSEcCtD
Lansoprazole—Headache—Epirubicin—thyroid cancer	6.77e-05	0.000215	CcSEcCtD
Lansoprazole—CYP1B1—Metabolism—HPGD—thyroid cancer	6.69e-05	0.00132	CbGpPWpGaD
Lansoprazole—Dizziness—Doxorubicin—thyroid cancer	6.61e-05	0.00021	CcSEcCtD
Lansoprazole—CYP2D6—Biological oxidations—RXRA—thyroid cancer	6.55e-05	0.00129	CbGpPWpGaD
Lansoprazole—CYP2C9—Biological oxidations—RXRA—thyroid cancer	6.5e-05	0.00128	CbGpPWpGaD
Lansoprazole—Nausea—Epirubicin—thyroid cancer	6.41e-05	0.000204	CcSEcCtD
Lansoprazole—CYP1A1—Metabolism—MINPP1—thyroid cancer	6.4e-05	0.00126	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	6.4e-05	0.00126	CbGpPWpGaD
Lansoprazole—Vomiting—Doxorubicin—thyroid cancer	6.35e-05	0.000202	CcSEcCtD
Lansoprazole—Rash—Doxorubicin—thyroid cancer	6.3e-05	0.0002	CcSEcCtD
Lansoprazole—Dermatitis—Doxorubicin—thyroid cancer	6.29e-05	0.0002	CcSEcCtD
Lansoprazole—Headache—Doxorubicin—thyroid cancer	6.26e-05	0.000199	CcSEcCtD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	6.16e-05	0.00121	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—HPGD—thyroid cancer	6.09e-05	0.0012	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—TPR—thyroid cancer	5.97e-05	0.00117	CbGpPWpGaD
Lansoprazole—Nausea—Doxorubicin—thyroid cancer	5.94e-05	0.000189	CcSEcCtD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	5.9e-05	0.00116	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PRKAR1A—thyroid cancer	5.87e-05	0.00115	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—MINPP1—thyroid cancer	5.86e-05	0.00115	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.59e-05	0.0011	CbGpPWpGaD
Lansoprazole—CYP1A2—Biological oxidations—RXRA—thyroid cancer	5.55e-05	0.00109	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—NDUFA13—thyroid cancer	5.44e-05	0.00107	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.43e-05	0.00107	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.32e-05	0.00105	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	5.3e-05	0.00104	CbGpPWpGaD
Lansoprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	5.3e-05	0.00104	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—MINPP1—thyroid cancer	5.23e-05	0.00103	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—TPR—thyroid cancer	5.21e-05	0.00103	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PRKAR1A—thyroid cancer	5.13e-05	0.00101	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—CHST14—thyroid cancer	5.11e-05	0.00101	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—MINPP1—thyroid cancer	5.11e-05	0.00101	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—NDUFA13—thyroid cancer	4.99e-05	0.000981	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—MINPP1—thyroid cancer	4.81e-05	0.000947	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—MINPP1—thyroid cancer	4.77e-05	0.000939	CbGpPWpGaD
Lansoprazole—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.7e-05	0.000924	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—CHST14—thyroid cancer	4.69e-05	0.000923	CbGpPWpGaD
Lansoprazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	4.51e-05	0.000887	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—SLC5A5—thyroid cancer	4.47e-05	0.000879	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—NDUFA13—thyroid cancer	4.45e-05	0.000876	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—NDUFA13—thyroid cancer	4.34e-05	0.000855	CbGpPWpGaD
Lansoprazole—CYP3A4—Biological oxidations—RXRA—thyroid cancer	4.28e-05	0.000843	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.18e-05	0.000823	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—CHST14—thyroid cancer	4.18e-05	0.000823	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—HPGD—thyroid cancer	4.12e-05	0.000811	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—NDUFA13—thyroid cancer	4.09e-05	0.000806	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—CHST14—thyroid cancer	4.08e-05	0.000804	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—MINPP1—thyroid cancer	4.08e-05	0.000803	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.06e-05	0.000799	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.04e-05	0.000794	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	4.04e-05	0.000794	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	3.97e-05	0.000782	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—SLC5A5—thyroid cancer	3.9e-05	0.000768	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—CHST14—thyroid cancer	3.85e-05	0.000757	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—TPR—thyroid cancer	3.84e-05	0.000756	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—CHST14—thyroid cancer	3.82e-05	0.000751	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PRKAR1A—thyroid cancer	3.78e-05	0.000744	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—HPGD—thyroid cancer	3.78e-05	0.000744	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—RXRA—thyroid cancer	3.75e-05	0.000738	CbGpPWpGaD
Lansoprazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	3.74e-05	0.000735	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.65e-05	0.000718	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—TPR—thyroid cancer	3.5e-05	0.000688	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—NDUFA13—thyroid cancer	3.47e-05	0.000682	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PRKAR1A—thyroid cancer	3.44e-05	0.000677	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.43e-05	0.000675	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—HPGD—thyroid cancer	3.37e-05	0.000664	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.34e-05	0.000658	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—HPGD—thyroid cancer	3.29e-05	0.000648	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—RXRA—thyroid cancer	3.28e-05	0.000645	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—CHST14—thyroid cancer	3.26e-05	0.000642	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.18e-05	0.000625	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.15e-05	0.000619	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—HPGD—thyroid cancer	3.1e-05	0.00061	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—HPGD—thyroid cancer	3.08e-05	0.000605	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.07e-05	0.000603	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.02e-05	0.000595	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—SLC5A5—thyroid cancer	2.88e-05	0.000566	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	2.87e-05	0.000565	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.77e-05	0.000545	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.74e-05	0.000538	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.7e-05	0.000531	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.68e-05	0.000527	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—HPGD—thyroid cancer	2.63e-05	0.000517	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—SLC5A5—thyroid cancer	2.62e-05	0.000515	CbGpPWpGaD
Lansoprazole—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.54e-05	0.0005	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—CHST14—thyroid cancer	2.52e-05	0.000495	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.49e-05	0.000491	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—RXRA—thyroid cancer	2.42e-05	0.000476	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PPARG—thyroid cancer	2.37e-05	0.000466	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—TPR—thyroid cancer	2.37e-05	0.000466	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.35e-05	0.000463	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	2.33e-05	0.000458	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—RXRA—thyroid cancer	2.2e-05	0.000433	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—TPR—thyroid cancer	2.17e-05	0.000427	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.14e-05	0.00042	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.13e-05	0.000419	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.13e-05	0.000419	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.11e-05	0.000415	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PPARG—thyroid cancer	2.07e-05	0.000407	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—HPGD—thyroid cancer	2.03e-05	0.000399	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—TPR—thyroid cancer	1.94e-05	0.000381	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.94e-05	0.000381	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	1.91e-05	0.000375	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—TPR—thyroid cancer	1.89e-05	0.000372	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	1.89e-05	0.000372	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTGS2—thyroid cancer	1.86e-05	0.000367	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.86e-05	0.000366	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—TPR—thyroid cancer	1.78e-05	0.000351	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—SLC5A5—thyroid cancer	1.77e-05	0.000349	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—TPR—thyroid cancer	1.77e-05	0.000348	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.75e-05	0.000345	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.74e-05	0.000342	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.73e-05	0.00034	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.66e-05	0.000327	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTGS2—thyroid cancer	1.63e-05	0.000321	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—PTEN—thyroid cancer	1.63e-05	0.00032	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.62e-05	0.00032	CbGpPWpGaD
Lansoprazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.6e-05	0.000314	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.58e-05	0.00031	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PPARG—thyroid cancer	1.53e-05	0.0003	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.52e-05	0.0003	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—TPR—thyroid cancer	1.51e-05	0.000297	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—RXRA—thyroid cancer	1.49e-05	0.000293	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.49e-05	0.000292	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.45e-05	0.000285	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.45e-05	0.000285	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—PTEN—thyroid cancer	1.42e-05	0.00028	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.42e-05	0.000279	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PPARG—thyroid cancer	1.39e-05	0.000273	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—RXRA—thyroid cancer	1.37e-05	0.000269	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.36e-05	0.000267	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.35e-05	0.000265	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.33e-05	0.000262	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.33e-05	0.000261	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.32e-05	0.00026	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.24e-05	0.000244	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—RXRA—thyroid cancer	1.22e-05	0.00024	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTGS2—thyroid cancer	1.2e-05	0.000236	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—RXRA—thyroid cancer	1.19e-05	0.000234	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.19e-05	0.000233	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—TPR—thyroid cancer	1.17e-05	0.000229	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.15e-05	0.000226	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.13e-05	0.000222	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—RXRA—thyroid cancer	1.12e-05	0.000221	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—RXRA—thyroid cancer	1.11e-05	0.000219	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTGS2—thyroid cancer	1.09e-05	0.000215	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.08e-05	0.000213	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.06e-05	0.000208	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—PTEN—thyroid cancer	1.05e-05	0.000206	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—PTEN—thyroid cancer	9.53e-06	0.000187	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—RXRA—thyroid cancer	9.49e-06	0.000187	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PPARG—thyroid cancer	9.4e-06	0.000185	CbGpPWpGaD
Lansoprazole—CYP4A11—Metabolism—AKT1—thyroid cancer	9.37e-06	0.000184	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.23e-06	0.000182	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—SLC5A5—thyroid cancer	8.72e-06	0.000172	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PPARG—thyroid cancer	8.62e-06	0.00017	CbGpPWpGaD
Lansoprazole—CYP2C18—Metabolism—AKT1—thyroid cancer	8.19e-06	0.000161	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PPARG—thyroid cancer	7.69e-06	0.000151	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PPARG—thyroid cancer	7.51e-06	0.000148	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTGS2—thyroid cancer	7.4e-06	0.000146	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—RXRA—thyroid cancer	7.33e-06	0.000144	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PPARG—thyroid cancer	7.08e-06	0.000139	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PPARG—thyroid cancer	7.02e-06	0.000138	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTGS2—thyroid cancer	6.78e-06	0.000133	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—PTEN—thyroid cancer	6.45e-06	0.000127	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTGS2—thyroid cancer	6.05e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP1B1—Metabolism—AKT1—thyroid cancer	6.04e-06	0.000119	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PPARG—thyroid cancer	5.99e-06	0.000118	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—PTEN—thyroid cancer	5.91e-06	0.000116	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTGS2—thyroid cancer	5.91e-06	0.000116	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.57e-06	0.00011	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTGS2—thyroid cancer	5.52e-06	0.000109	CbGpPWpGaD
Lansoprazole—ABCG2—Metabolism—AKT1—thyroid cancer	5.49e-06	0.000108	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—PTEN—thyroid cancer	5.28e-06	0.000104	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—PTEN—thyroid cancer	5.15e-06	0.000101	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—PTEN—thyroid cancer	4.85e-06	9.55e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—PTEN—thyroid cancer	4.81e-06	9.47e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTGS2—thyroid cancer	4.72e-06	9.28e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PPARG—thyroid cancer	4.63e-06	9.1e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—PTEN—thyroid cancer	4.11e-06	8.09e-05	CbGpPWpGaD
Lansoprazole—CYP1A1—Metabolism—AKT1—thyroid cancer	3.72e-06	7.31e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.64e-06	7.16e-05	CbGpPWpGaD
Lansoprazole—CYP2C8—Metabolism—AKT1—thyroid cancer	3.41e-06	6.71e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—PTEN—thyroid cancer	3.17e-06	6.25e-05	CbGpPWpGaD
Lansoprazole—CYP2C19—Metabolism—AKT1—thyroid cancer	3.04e-06	5.99e-05	CbGpPWpGaD
Lansoprazole—ABCB1—Metabolism—AKT1—thyroid cancer	2.97e-06	5.84e-05	CbGpPWpGaD
Lansoprazole—CYP2D6—Metabolism—AKT1—thyroid cancer	2.8e-06	5.5e-05	CbGpPWpGaD
Lansoprazole—CYP2C9—Metabolism—AKT1—thyroid cancer	2.77e-06	5.46e-05	CbGpPWpGaD
Lansoprazole—CYP1A2—Metabolism—AKT1—thyroid cancer	2.37e-06	4.66e-05	CbGpPWpGaD
Lansoprazole—CYP3A4—Metabolism—AKT1—thyroid cancer	1.83e-06	3.6e-05	CbGpPWpGaD
